The global postmenopausal osteoporosis treatment market is poised for significant growth, with a projected market value of USD 13.1 billion in 2024, set to increase to USD 23.0 billion by 2034, according to Future Market Insights’ latest market analysis. The market is expected to grow at a robust compound annual growth rate (CAGR) of 5.8% over the next decade.
Strong Demand for Bisphosphonates and Emerging Therapeutics:
The growing demand for medications to treat postmenopausal osteoporosis is predominantly driven by the continued efficacy and cost-effectiveness of bisphosphonates, the most commonly prescribed class of drugs for the condition. As per the analysis, the bisphosphonate segment is anticipated to grow at a CAGR of 5.6% through 2034, reinforcing its market dominance.
Unlock Key Market Trends: Get Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d3138333632
Key Drivers of Market Growth:
Several factors are expected to fuel the postmenopausal osteoporosis market’s expansion during the forecast period, including:
- Rising Geriatric Population: The global increase in elderly individuals, particularly women, is contributing to higher cases of postmenopausal osteoporosis.
- Increasing Diagnostic Rates: Advances in diagnostic techniques, allowing for earlier and more accurate detection of osteoporosis, are enabling better management and treatment outcomes.
- New Drug Approvals: Ongoing research and development efforts from leading pharmaceutical companies are expected to introduce new treatments with improved efficacy and safety profiles, further accelerating market growth.
Women with postmenopausal osteoporosis commonly rely on treatments such as bisphosphonates, raloxifene, and denosumab, which have been proven to slow bone loss, enhance bone density, and prevent fractures. The availability of new therapies and diagnostic tools is expected to enhance patient outcomes and contribute to growing treatment adoption worldwide.
Outlook for the Postmenopausal Osteoporosis treatment Industry:
As the number of postmenopausal women increases globally, the prevalence of osteoporosis is expected to continue rising, driving sustained demand for effective treatments. The combination of an aging population, enhanced diagnostic capabilities, and the availability of new and more effective drugs is creating a fertile landscape for market expansion.
With leading manufacturers investing heavily in research and development, the global postmenopausal osteoporosis market is set to experience transformative growth, benefiting patients and driving advancements in the therapeutic landscape.
Heightened Demand for Market Data: Our Full Report Provides Extensive Trend Analysis! https://www.futuremarketinsights.com/reports/postmenopausal-osteoporosis-treatment-market
Key Takeaways from the Report:
- The global market is estimated to be valued at USD 23.0 billion in 2034.
- By drug type, bisphosphonates segment is set to register a CAGR of 5.6% through 2034.
- Based on distribution channel, hospital pharmacies category will grow at 5.4% CAGR.
- Sales in the United States are predicted to total USD 4.0 billion by 2034.
- China is anticipated to record a CAGR of 6.6% between 2024 and 2034.
- Demand in South Korea is forecast to surge at 8.0% CAGR through 2034.
“As the global geriatric population continues to increase rapidly, there will be a corresponding rise in the prevalence of postmenopausal osteoporosis. This, in turn, is set to create growth prospects for the postmenopausal osteoporosis treatment industry through 2034,” says a lead Future Market Insights (FMI) analyst.
Who is Winning?
Leading players in the postmenopausal osteoporosis treatment market include Sanofi S.A., Amgen Inc., Eli Lilly and Company, Novartis International AG, Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Roche Holding AG, Johnson & Johnson, Actavis Pharma, Inc. (now part of Teva Pharmaceuticals), Mylan N.V. (now part of Viatris Inc.), and Accord Healthcare Limited.
Top players are focusing on new product launches and approvals to stay relevant in the market and boost their revenues. They are also utilizing strategies like partnerships, distribution agreements, collaborations, mergers, and acquisitions to gain a competitive edge in the market.
Recent Developments:
- In April 2019, the American multinational biopharmaceutical company Amgen and UCB received the United States Food and Drug Administration (FDA) approval for EVENITY (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis.
- In July 2022, Edirol was launched in China by Chugai Pharma China Co., Ltd. for the treatment of postmenopausal osteoporosis.
Unlock Key Insights into Healthcare Market Growth! https://www.futuremarketinsights.com/industry-analysis/therapy-area
Postmenopausal Osteoporosis Therapeutics Market Segmentation:
By Drug Type:
- Bisphosphonates
- Vitamin D3
- Estrogen Agonist/Antagonist
- Hormone Replacement Therapy
- Parathyroid Hormone Therapy
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
